The FDA accepted the resubmitted Biologics License Application (BLA) from Atara Biotherapeutics, Inc. on September 4, 2025. Greg Ciongoli also assumed the role of Board Chair.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA accepted the resubmitted Biologics License Application (BLA) from Atara Biotherapeutics, Inc. on September 4, 2025. Greg Ciongoli also assumed the role of Board Chair.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Atara Biotherapeutics, Inc.
clinical-stage biotechnology company
Nothing else this week.
Related events
- The FDA placed a clinical hold on the IND application for the company Aardvark.
- FDA approval enables commercial opportunity involving CBRE Group.
- The FDA has issued a Major Amendment regarding AxoGen's submission on August 25, 2025.
- Modular is seeking FDA clearance for its Pivot product.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
Coverage
Newest first; wire copies grouped- Business WireAtara Biotherapeutics Announces Changes to Its Board of Directors THOUSAND OAKS, Calif, September 03, 2025--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunothera